Death by PCA
The Case
A healthy 21-year-old pregnant woman delivered a healthy baby via Caesarean section after an uncomplicated pregnancy. Two hours after delivery, the post-anesthesia care unit (PACU) nurse removed the patient's epidural catheter (placed prior to Caesarean section) and implemented an order for a morphine patient-controlled analgesia (PCA) with a 2-mg bolus, 6-minute lockout, and a 4-hour limit of 30 mg. Two concentrations of morphine are normally available for PCA use, 1 mg/mL and 5 mg/mL. The nurse used a 5 mg/mL morphine cassette because a 1 mg/mL cassette was not available. Upon admission to the ward 3 hours after delivery, the ward nurse reviewed the history settings on the PCA pump and confirmed the pump settings were consistent with the order. However, she did not read the label on the cassette, open the pump, or assess the volume being infused.
Four hours after delivery, the patient complained of itching after breastfeeding her infant. The nurse administered 25 mg Benadryl intravenously followed by a second 25-mg dose of Benadryl 45 minutes later. Six hours after delivery the patient was alert, oriented, and awake. Later in the evening the patient was found asleep and snoring. Her vitals were within normal range and the nurse noted that 20 mg of morphine had been infused. Thirty minutes later the patient had no detectable pulse or respirations. Despite resuscitation efforts, she was pronounced dead 7.5 hours after initiation of the PCA.
Autopsy revealed a toxic concentration of morphine. The available evidence is consistent with a concentration programming error where morphine 1 mg/mL was entered in the infusion pump instead of 5 mg/mL.
The Commentary
This case highlights many of the persistent complexities that clinicians face when dealing with patient-controlled analgesia (PCA). Like many iatrogenic errors, active and latent decisions (1) led to a tragic patient outcome. As early as 2003, mortality from PCA use was thought to be a low likelihood event, ranging between 1:33,000 to 1:338,800 cases.(2) A more recent analysis from 500 hospitals found that 6.5% of PCA errors resulted in harm, as compared with 1.5% of general medication errors.(3) Despite advances in patient safety awareness, such events are far too common and are not limited to the United States health care system.(2,4) The true incidence and burden of PCA errors remains unknown.
Opioids are the most commonly used class of medications for postoperative pain management.(5,6) For more than four decades and now in almost every developed country, PCA remains an effective means for postoperative pain management. PCA differs from nurse-controlled analgesia, which usually involves intermittent, intramuscular injections of analgesic agents. In the latter, patients depend on nursing staff to administer medication. Favorable attributes of PCA use include rapid onset of analgesia, avoidance of first-pass hepatic effect, decreased surgical complication rates, shortened stays, and lower risk of litigation.(3,4)
PCA errors are a subset of medication errors and can be categorized (and should be reported) using common medication error frameworks that describe severity (patient outcome), type of error, cause of error, contributing factors, and product involvement. Although PCA errors can originate in each phase of the medication use process (Table 1), it is the point of drug administration that is often implicated, such as excessive doses (7) (as evident in this case) or the use of the wrong opioid product.(3) Even with recent use of human factors engineering approaches to designing safer user interfaces (8), the majority of errors still originate with individuals making mistakes rather than being equipment related.(3,4)
In the current case, at least three opportunities to detect the error were missed. First, there was failure in the independent double check during the device set up. Independent double checks rank high among the many recommendations that have been suggested as a means to reduce errors (7,9), although this practice has been recently scrutinized and the evidence is insufficient to either support or refute its true value.(10) Contributing to the failed double check was the fact that the routinely stocked dose of morphine (1 mg/mL) was replaced with a higher dose (5 mg/mL). Thus, confirmation bias (9) likely occurred with the post-anesthesia care unit (PACU) nurses. Confirmation bias is a selective type of thinking whereby one tends to read or hear what they expect. In this case, the staff likely saw only the name of the product and then assumed the "routine dose" and, as a result, overlooked the dose variation. Validation of dose and product accuracy, however, could be accomplished through a bedside barcode medication administration (BCMA) process, which is clearly superior to and more reliable than independent double checks.(11)
The second missed opportunity deals with the patient's persistent pruritus. This symptom should have provoked the clinical staff to further assess the patient and the infusion. Opioids have a number of adverse effects, including pruritus, bradypnea, hypoxia, nausea, vomiting, sedation, urinary retention, and death.(6) Compounding the oversight, diphenhydramine, a sedating antihistamine, was administered twice—which should have been another red flag. The final opportunity to identify the opioid overdose before the patient was permanently harmed pertains to the presence of snoring respiration—a finding that suggests deeper sedation. Sedation generally precedes respiratory depression.
Missing from the case at hand is any discussion on the use of pulse oximetry, capnography, or other proven monitoring technology. In the not-too-distant past, the addition of either device required supplemental equipment. Newer PCA pumps (e.g., smart pumps) can supplement clinicians' activities by integrating capnography within the pump and temporarily suspend infusions when physiological parameters are breached.(5,12) Newer technologies offer drug error reduction systems, drug libraries (11), and programmable features.(11,13) For this case, capnography alarms would have alerted staff to a deteriorating clinical condition ahead of apnea.
Several organizations have publically shared experiences with comprehensive safety initiatives surrounding PCA use.(5,7,11,12,14) Facilities in Pittsburgh have reported that PCA safety has been significantly enhanced by the low cost intervention of standardizing the PCA prescribing and administering processes across the community. An understanding of, and investment in, the medication use process offers the best protection to avert similar errors. Patient safety begins with a multidisciplinary team of clinicians and organizational leaders committed to practicing safe medication use and embracing strategies that will reduce the burden of medication errors (Table 2). Of particular promise are the technology advances in electronic order entry, appropriately stocked medication dispensing cabinets intricately linked to the pharmacy information system, fully deployed bedside BCMA with a smart pump, and capnography with corresponding pulse oximetry capable of wireless monitoring. Ultimately, having a trained staff and appropriately integrated technology will become the new organizational norm.
Take-Home Points
- PCA is widely used and is generally an effective method of postoperative pain management.
- While deaths from PCAs are rare, they can occur and this heightens the importance of developing safe processes surrounding PCA use.
- Safe PCA use is highly dependent on a team comprised of clinicians, administrators, biomedical engineers, and quality improvement personnel.
- Organizations that employ PCAs must adopt and integrate technology—such as bedside barcoding and monitoring with capnography and oximetry—in order to facilitate safe medication use.
Rodney W. Hicks, PhD, RN, FNP Professor College of Graduate Nursing Western University of Health Sciences Pomona, CA
References
1. Vincent C, Taylor-Adams S, Stanhope N. Framework for analysing risk and safety in clinical medicine. BMJ. 1998;316:1154-1157. [go to PubMed]
2. Vicente KJ, Kada-Bekhaled K, Hillel G, Cassano A, Orser BA. Programming errors contribute to death from patient-controlled analgesia: case report and estimate of probability. Can J Anaesth. 2003;50:328-332. [go to PubMed]
3. Hicks RW, Sikirica V, Nelson W, Schein JR, Cousins DD. Medication errors involving patient-controlled analgesia. Am J Health Syst Pharm. 2008;65:429-440. [go to PubMed]
4. Ahmad I, Thompson A, Frawley M, Hu P, Heffernan A, Power C. Five-year experience of critical incidents associated with patient-controlled analgesia in an Irish University Hospital. Ir J Med Sci. 2010;179:393-397. [go to PubMed]
5. Maddox RR, Oglesby H, Williams CK, Fields M, Danello S. Continuous respiratory monitoring and a "smart" infusion system improve safety of patient-controlled analgesia in the postoperative period. In: Henriksen K, Battles JB, Keyes MA, Grady ML, eds. Advances in Patient Safety: New Directions and Alternative Approaches (Vol. 4: Technology and Medication Safety). Rockville, MD: Agency for Healthcare Research and Quality; August 2008. AHRQ Publication No. 08-0034-4. [go to PubMed]
6. Viscusi ER. Patient-controlled drug delivery for acute postoperative pain management: a review of current and emerging technologies. Reg Anesth Pain Med. 2008;33:146-158. [go to PubMed]
7. Paul JE, Bertram B, Antoni K, et al. Impact of a comprehensive safety initiative on patient-controlled analgesia errors. Anesthesiology. 2010;113:1427-1432. [go to PubMed]
8. Ladak SS, Chan VW, Easty T, Chagpar A. Right medication, right dose, right patient, right time, and right route: how do we select the right patient-controlled analgesia (PCA) device? Pain Manag Nurs. 2007;8:140-145. [go to PubMed]
9. White RE, Trbovich PL, Easty AC, Savage P, Trip K, Hyland S. Checking it twice: an evaluation of checklists for detecting medication errors at the bedside using a chemotherapy model. Qual Saf Health Care. 2010;19:562-567. [go to PubMed]
10. Alsulami Z, Conroy S, Choonara I. Double checking the administration of medicines: what is the evidence? A systematic review. Arch Dis Child. 2012;97:833-837. [go to PubMed]
11. Tran M, Ciarkowski S, Wagner D, Stevenson JG. A case study on the safety impact of implementing smart patient-controlled analgesic pumps at a tertiary care academic medical center. Jt Comm J Qual Patient Saf. 2012;38:112-119. [go to PubMed]
12. McCarter T, Shaik Z, Scarfo K, Thompson LJ. Capnography monitoring enhances safety of postoperative patient-controlled analgesia. Am Health Drug Benefits. 2008;1:28-35. [Available at]
13. Husch M, Sullivan C, Rooney D, et al. Insights from the sharp end of intravenous medication errors: implications for infusion pump technology. Qual Saf Health Care. 2005;14:80-86. [go to PubMed]
14. Moss J. Reducing errors during patient-controlled analgesia therapy through failure mode and effects analysis. Jt Comm J Qual Patient Saf. 2010;36:359-364. [go to PubMed]
15. Hicks RW, Becker SC, Cousins DD. MEDMARX Data Report: A Chartbook of Medication Error Findings from the Perioperative Setting from 1998–2005. Rockville, MD: United States Pharmacopeia; 2006.
16. Patel A, Viscusi ER, Schechter L. Extended-release epidural morphine. In: Sinatra RS, Jahr JS, Watkins-Pitchford JM, eds. The Essence of Analgesia and Analgesics. New York, NY: Cambridge University Press; 2010. ISBN: 9780521144506.
Tables
Table 1. The Medication Use Process.(15)
Step in Medication Use Process | Defined |
---|---|
Procuring and Storage | The formal action of how organizations obtain and store products |
Prescribing | The action of a legitimate prescriber to issue a medication order |
Transcribing | Anything that involves or is related to the act of transcribing an order by someone other than the prescriber for order processing |
Dispensing | Begins with a pharmacist's assessment of a medication order and continues to the point of releasing the product for use by another health care professional |
Administering | The action during which the medication product and the patient intersect |
Monitoring | Involves evaluating the patient's physical, emotional, or psychological response to the medication and the recording such findings |
Table 2. Roles in the medication use process (MUP) that promote safe use of PCA.
POINT IN MUP | RESPONSIBLE PARTY (PARTIES) | SAFETY SOLUTIONS OF MOST PROMISING BENEFITS |
---|---|---|
Procuring | Chief executive officer Chief operating officer Chief nursing officer Chief medical officer Chief information officer |
|
Pharmacy and therapeutics committee (P&T) | ||
Purchasing |
| |
Storing | Pharmacy |
|
Prescribing | Prescribing | |
Transcribing | Chief executive officer Chief operating officer Chief nursing officer Chief medical officer Chief information officer Clinical staff |
|
Dispensing | Pharmacy |
|
Administering | Licensed clinicians (includes physicians, nurses, therapists) |
|
Monitoring | Biomedical department Quality improvement department |
|
Clinical staff |
| |
Chief executive officer Chief operating officer Chief nursing officer Chief medical officer Chief information officer Clinical staff |
|